{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000012","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.725607+00:00","generated_at":"2026-05-25T22:33:06.643382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharma Q4 net rev $190.6M (+44.8%), adj EPS $1.63; raises 2025 guidance","bullets":["Record Q4 net rev $190.6M (+44.8% YoY); organic growth (ex-Alimera) +23.8%.","Rare Disease rev $87.0M: Cortrophin Gel $59.4M (+42.3%), ILUVIEN/YUTIQ $27.6M.","Adj. non-GAAP EBITDA $50.0M (+65.7%); diluted GAAP loss per share $0.55.","Adj. non-GAAP diluted EPS $1.63 vs $1.00 in prior year quarter.","2025 guidance raised: rev $756-776M, adj. EBITDA $190-200M, adj. EPS $6.12-6.49."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000012","json":"https://secwatch.observer/filing/0001023024-25-000012.json","markdown":"https://secwatch.observer/filing/0001023024-25-000012.md","text":"https://secwatch.observer/filing/0001023024-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/0001023024-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/ani-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T22:33:06.643382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}